Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment

  • Koo, Taeryool (Department of Radiation Oncology, Hallym University Chuncheon Sacred Heart Hospital) ;
  • Kim, In Ah (Department of Radiation Oncology, Seoul National University Bundang Hospital)
  • Received : 2016.02.02
  • Accepted : 2016.02.18
  • Published : 2016.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Overexpression of human epidermal growth factor receptor 2 (HER2) is found in about 20% of breast cancer patients. With treatment using trastuzumab, an anti-HER2 monoclonal antibody, systemic control is improved. Nonetheless, the incidence of brain metastasis does not be improved, rather seems to be increased in HER2-positive breast cancer. The mainstay treatment for brain metastases is radiotherapy. According to the number of metastatic lesions and performance status of patients, radiosurgery or whole brain radiotherapy can be performed. The concurrent use of a radiosensitizer further improves intracranial control. Due to its large molecular weight, trastuzumab has a limited ability to cross the blood-brain barrier. However, small tyrosine kinase inhibitors such as lapatinib, has been noted to be a promising agent that can be used as a radiosensitizer to affect HER2-positive breast cancer. This review will outline general management of brain metastases and will focus on preclinical findings regarding the radiosensitizing effect of small molecule HER2 targeting agents.

Keywords

References

  1. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. https://doi.org/10.1056/NEJMoa052122
  2. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84. https://doi.org/10.1016/S0140-6736(09)61964-4
  3. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85. https://doi.org/10.1200/JCO.2005.07.032
  4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. https://doi.org/10.1200/JCO.2002.20.3.719
  5. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86. https://doi.org/10.1200/JCO.2008.19.8481
  6. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7. https://doi.org/10.1200/JCO.2009.25.9820
  7. Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8. https://doi.org/10.1158/0008-5472.CAN-06-3316
  8. Yonemori K, Tsuta K, Ono M, et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basaltype breast cancer but not HER2/neu-positive breast cancer. Cancer 2010;116:302-8. https://doi.org/10.1002/cncr.24735
  9. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011;117:1837-46. https://doi.org/10.1002/cncr.25771
  10. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7. https://doi.org/10.1002/cncr.11436
  11. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008;112:2359-67. https://doi.org/10.1002/cncr.23468
  12. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500. https://doi.org/10.1056/NEJM199002223220802
  13. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-90. https://doi.org/10.1002/ana.410330605
  14. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485-9.
  15. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-72. https://doi.org/10.1016/S0140-6736(04)16250-8
  16. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91. https://doi.org/10.1001/jama.295.21.2483
  17. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
  18. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012;4:CD003869.
  19. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803. https://doi.org/10.1016/S0360-3016(98)00442-8
  20. Chang WS, Kim HY, Chang JW, Park YG, Chang JH. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? J Neurosurg 2010;113 Suppl:73-8.
  21. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014;15:387-95. https://doi.org/10.1016/S1470-2045(14)70061-0
  22. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 2006;64:898-903. https://doi.org/10.1016/j.ijrobp.2005.08.035
  23. Karlsson B, Hanssens P, Wolff R, Soderman M, Lindquist C, Beute G. Thirty years' experience with Gamma Knife surgery for metastases to the brain. J Neurosurg 2009;111:449-57. https://doi.org/10.3171/2008.10.JNS08214
  24. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22:157-65. https://doi.org/10.1200/JCO.2004.05.128
  25. Regine WF, Scott C, Murray K, Curran W. Neurocognitive outcome in brain metastases patients treated with acceleratedfractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 2001;51:711-7. https://doi.org/10.1016/S0360-3016(01)01676-5
  26. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388-95. https://doi.org/10.1016/j.ijrobp.2007.03.048
  27. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:1037-44. https://doi.org/10.1016/S1470-2045(09)70263-3
  28. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013;31:65-72.
  29. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2100-8. https://doi.org/10.1200/JCO.2013.54.0955
  30. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stemcell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 2014;32:3810-6. https://doi.org/10.1200/JCO.2014.57.2909
  31. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14. https://doi.org/10.1602/neurorx.2.1.3
  32. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51. https://doi.org/10.1200/JCO.2000.18.11.2349
  33. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 2002;9:683-8.
  34. d'Avella D, Cicciarello R, Angileri FF, Lucerna S, La Torre D, Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl 1998;71:282-4.
  35. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-8. https://doi.org/10.1097/01.cad.0000236313.50833.ee
  36. Chargari C, Idrissi HR, Pierga JY, et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int J Radiat Oncol Biol Phys 2011;81:631-6. https://doi.org/10.1016/j.ijrobp.2010.06.057
  37. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100:1092-103. https://doi.org/10.1093/jnci/djn216
  38. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 2012;29:770-81. https://doi.org/10.1007/s11095-011-0601-8
  39. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9. https://doi.org/10.1200/JCO.2007.12.3588
  40. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9. https://doi.org/10.1158/1078-0432.CCR-08-1080
  41. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases: the UK experience. Br J Cancer 2010;102:995-1002. https://doi.org/10.1038/sj.bjc.6605586
  42. de Azambuja E, Zardavas D, Lemort M, et al. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Ann Oncol 2013;24:2985-9. https://doi.org/10.1093/annonc/mdt359
  43. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013;14:64-71. https://doi.org/10.1016/S1470-2045(12)70432-1
  44. Iwata H, Narabayashi M, Ito Y, et al. A phase II study of lapatinib for brain metastases in patients with HER2- overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol 2013;18:621-8. https://doi.org/10.1007/s10147-012-0444-2
  45. Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011;105:613-20. https://doi.org/10.1007/s11060-011-0629-y
  46. Belkacemi Y, Kuten A. Are volumetric changes of brain metastases the best evaluation of efficacy? J Clin Oncol 2008;26:5137-8. https://doi.org/10.1200/JCO.2008.19.0306
  47. Gori S, Lunardi G, Inno A, et al. Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. Ann Oncol 2014;25:912-3. https://doi.org/10.1093/annonc/mdu041
  48. Morikawa A, Peereboom DM, Thorsheim HR, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol 2015;17:289-95. https://doi.org/10.1093/neuonc/nou141
  49. Sambade MJ, Kimple RJ, Camp JT, et al. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys 2010;77:575-81. https://doi.org/10.1016/j.ijrobp.2009.12.063
  50. Lin NU, Freedman RA, Ramakrishna N, et al. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013;142:405-14. https://doi.org/10.1007/s10549-013-2754-0

Cited by

  1. Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells vol.7, pp.48, 2016, https://doi.org/10.18632/oncotarget.12597
  2. Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP vol.27, pp.14, 2016, https://doi.org/10.1089/ars.2016.6889
  3. Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer vol.3, pp.1, 2016, https://doi.org/10.1016/j.cdtm.2017.01.004
  4. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy vol.12, pp.None, 2016, https://doi.org/10.1186/s13014-017-0774-3
  5. Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro stud vol.52, pp.1, 2016, https://doi.org/10.3892/ijo.2017.4204
  6. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status vol.138, pp.2, 2018, https://doi.org/10.1007/s11060-018-2798-4
  7. Practical consensus recommendations on Her2 +ve breast cancer with solitary brain mets vol.7, pp.2, 2018, https://doi.org/10.4103/sajc.sajc_116_18
  8. Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort vol.24, pp.6, 2018, https://doi.org/10.1111/tbj.13111
  9. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice vol.78, pp.21, 2018, https://doi.org/10.1158/0008-5472.can-18-0363
  10. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy vol.172, pp.3, 2016, https://doi.org/10.1007/s10549-018-4966-9
  11. Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report vol.18, pp.None, 2016, https://doi.org/10.1186/s12885-018-4116-0
  12. Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study vol.22, pp.None, 2016, https://doi.org/10.4048/jbc.2019.22.e1
  13. Trastuzumab-Modified Gold Nanoparticles Labeled with 211At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer vol.9, pp.4, 2016, https://doi.org/10.3390/nano9040632
  14. Clinical Perspectives in Brain Metastasis vol.10, pp.6, 2016, https://doi.org/10.1101/cshperspect.a037051
  15. Brain and heart‐specific death in cancer patients: Population‐based study vol.10, pp.17, 2021, https://doi.org/10.1002/cam4.4069